Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen cut to Hold at Argus on expected earnings decline
- Biogen downgraded to Hold from Buy at Argus
- Biogen announces U.S. FDA granted Fast Track designation to BIIB080
- Organon acquires rights for Tofidence from Biogen
- Biogen’s Favorable Outlook: Navigating Regulatory Challenges and Safety Advantages Justify Buy Rating